Safety, Tolerability and Effects of L-Arginine in Boys With Dystrophinopathy on Corticosteroids
|ClinicalTrials.gov Identifier: NCT01388764|
Recruitment Status : Completed
First Posted : July 7, 2011
Last Update Posted : July 3, 2012
|Condition or disease||Intervention/treatment||Phase|
|Dystrophinopathy Duchenne Muscular Dystrophy Becker's Muscular Dystrophy||Drug: L-arginine||Phase 1|
Dystrophinopathy is a muscular dystrophy (includes Duchenne or Becker's Muscular Dystrophy) that can be a lethal muscle disorder resulting from defects in the gene for dystrophin, a structural protein required to maintain muscle integrity. Absence of functional dystrophin leaves the muscle membrane vulnerable to damage during contraction. This damage can be exacerbated by an inflammatory response leading to myofiber necrosis.
L-arginine is a widely available dietary supplement amino acid postulated to affect dystrophinopathy in several favorable ways: upregulation of utrophin, vasodilation in muscle via nitric oxide, enhanced synthesis of creatine, increase levels of growth hormone.
We hypothesize that administration of L-arginine may increase levels of creatine and growth hormone and in turn reduce the extent of myofiber damage in our patients with dystrophinopathy
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||7 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pilot Study: To Assess the Safety, Tolerability and Effects of L-Arginine on Muscles in Boys With Dystrophinopathy on Corticosteroids|
|Study Start Date :||January 2012|
|Actual Primary Completion Date :||May 2012|
|Actual Study Completion Date :||May 2012|
Subjects will receive oral L-Arginine (0.3 grams/kg/day, divided 2 times per day, not to exceed 14 grams/day)
- MRI/MRS of calf muscle [ Time Frame: Day 0 and Day 30 ]MRI/MRS will be performed of the calf muscle in all subjects (N=8) to assess muscle signal abnormalities on MRI and creatine levels on MRS, done at the start of the study (Day 0) and at the end of the study (Day 30), after 30 days of L-arginine administration.
- Blood tests [ Time Frame: Day 0 and Day 30 ]We will obtain safety labs [complete blood count (CBC) and comprehensive metabolic panel (CMP)] from all subjects (N =8), at day 0 and day 30, after 30 days of oral L-argninine administration.
- Assessment of muscle strength and function [ Time Frame: Day 0 and Day 30 ]Measurements of upper and lower extremity strength will be performed using a hand-held dynamometer. Functional tests will also be performed which include time to walk specified distances and time to climb stairs.
- Pulmonary function tests [ Time Frame: Day 0 and Day 30 ]Subjects will have pulmonary function studies to assess forced vital capacity
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01388764
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|Principal Investigator:||Namita Goyal, MD||Massachusetts General Hospital|